220 related articles for article (PubMed ID: 28650518)
1. A simple in silico strategy identifies candidate biomarkers for the diagnosis of liver fibrosis in morbidly obese subjects.
Giraudi PJ; Gambaro SE; Ornelas Arroyo S; Chackelevicius CM; Giuricin M; Silvestri M; Macor D; Crocé LS; Bonazza D; Soardo G; de Manzini N; Zanconati F; Tiribelli C; Palmisano S; Rosso N
Liver Int; 2018 Jan; 38(1):155-163. PubMed ID: 28650518
[TBL] [Abstract][Full Text] [Related]
2. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease.
Joo SK; Kim W; Kim D; Kim JH; Oh S; Lee KL; Chang MS; Jung YJ; So YH; Lee MS; Bae JM; Kim BG
Liver Int; 2018 Feb; 38(2):331-341. PubMed ID: 28796410
[TBL] [Abstract][Full Text] [Related]
3. Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese.
Ooi GJ; Burton PR; Doyle L; Wentworth JM; Bhathal PS; Sikaris K; Cowley MA; Roberts SK; Kemp W; O'Brien PE; Brown WA
Obes Surg; 2017 Jan; 27(1):115-125. PubMed ID: 27220852
[TBL] [Abstract][Full Text] [Related]
4. Severe Vitamin D Deficiency Is Not Associated with Liver Damage in Morbidly Obese Patients.
Anty R; Hastier A; Canivet CM; Patouraux S; Schneck AS; Ferrari-Panaia P; Ben-Amor I; Saint-Paul MC; Gugenheim J; Gual P; Iannelli A; Tran A
Obes Surg; 2016 Sep; 26(9):2138-2143. PubMed ID: 26787197
[TBL] [Abstract][Full Text] [Related]
5. Ficolin-2 Plasma Level Assesses Liver Fibrosis in Non-Alcoholic Fatty Liver Disease.
Giraudi PJ; Salvoza N; Bonazza D; Saitta C; Lombardo D; Casagranda B; de Manzini N; Pollicino T; Raimondo G; Tiribelli C; Palmisano S; Rosso N
Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269955
[TBL] [Abstract][Full Text] [Related]
6. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study.
Younes R; Rosso C; Petta S; Cucco M; Marietti M; Caviglia GP; Ciancio A; Abate ML; Cammà C; Smedile A; Craxì A; Saracco GM; Bugianesi E
Liver Int; 2018 Apr; 38(4):715-723. PubMed ID: 29028281
[TBL] [Abstract][Full Text] [Related]
8. Measurement of Liver Stiffness with 2D-Shear Wave Elastography (2D-SWE) in Bariatric Surgery Candidates Reveals Acceptable Diagnostic Yield Compared to Liver Biopsy.
Jamialahmadi T; Nematy M; Jangjoo A; Goshayeshi L; Rezvani R; Ghaffarzadegan K; Nooghabi MJ; Shalchian P; Zangui M; Javid Z; Doaei S; Rajabzadeh F
Obes Surg; 2019 Aug; 29(8):2585-2592. PubMed ID: 31077025
[TBL] [Abstract][Full Text] [Related]
9. Performance of non-invasive models of fibrosis in predicting mild to moderate fibrosis in patients with non-alcoholic fatty liver disease.
Siddiqui MS; Patidar KR; Boyett S; Luketic VA; Puri P; Sanyal AJ
Liver Int; 2016 Apr; 36(4):572-9. PubMed ID: 26713759
[TBL] [Abstract][Full Text] [Related]
10. Preliminary Evaluation of Acoustic Radiation Force Impulse Shear Wave Imaging to Detect Hepatic Fibrosis in Morbidly Obese Patients Before Bariatric Surgery.
Praveenraj P; Gomes RM; Basuraju S; Kumar S; Senthilnathan P; Parathasarathi R; Rajapandian S; Palanivelu C
J Laparoendosc Adv Surg Tech A; 2016 Mar; 26(3):192-5. PubMed ID: 26895403
[TBL] [Abstract][Full Text] [Related]
11. Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis.
Loomba R; Jain A; Diehl AM; Guy CD; Portenier D; Sudan R; Singh S; Faulkner C; Richards L; Hester KD; Okada L; Li XJ; Mimms L; Abdelmalek MF
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1867-1876.e3. PubMed ID: 30448594
[TBL] [Abstract][Full Text] [Related]
12. Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease.
Lefere S; Van de Velde F; Devisscher L; Bekaert M; Raevens S; Verhelst X; Van Nieuwenhove Y; Praet M; Hoorens A; Van Steenkiste C; Van Vlierberghe H; Lapauw B; Geerts A
Int J Obes (Lond); 2017 Aug; 41(8):1207-1213. PubMed ID: 28461687
[TBL] [Abstract][Full Text] [Related]
13. Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity.
Di Mauro S; Scamporrino A; Petta S; Urbano F; Filippello A; Ragusa M; Di Martino MT; Scionti F; Grimaudo S; Pipitone RM; Privitera G; Di Pino A; Scicali R; Valenti L; Dongiovanni P; Fracanzani A; Rabuazzo AM; Craxì A; Purrello M; Purrello F; Piro S
Liver Int; 2019 Sep; 39(9):1742-1754. PubMed ID: 31169972
[TBL] [Abstract][Full Text] [Related]
14. The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease.
Mansoor S; Yerian L; Kohli R; Xanthakos S; Angulo P; Ling S; Lopez R; Christine CK; Feldstein AE; Alkhouri N
Dig Dis Sci; 2015 May; 60(5):1440-7. PubMed ID: 25540086
[TBL] [Abstract][Full Text] [Related]
15. Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology.
Calvo N; Beltrán-Debón R; Rodríguez-Gallego E; Hernández-Aguilera A; Guirro M; Mariné-Casadó R; Millá L; Alegret JM; Sabench F; del Castillo D; Vinaixa M; Rodríguez MÀ; Correig X; García-Álvarez R; Menendez JA; Camps J; Joven J
World J Gastroenterol; 2015 Jun; 21(24):7529-44. PubMed ID: 26140000
[TBL] [Abstract][Full Text] [Related]
16. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease.
Maleki I; Aminafshari MR; Taghvaei T; Hosseini V; Rafiei A; Torabizadeh Z; Barzin M; Orang E
World J Gastroenterol; 2014 Sep; 20(35):12566-73. PubMed ID: 25253959
[TBL] [Abstract][Full Text] [Related]
17. Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease.
Yang M; Jiang L; Wang Y; Li X; Zou Z; Han T; Nan Y; Lu F; Zhao J
J Gastrointestin Liver Dis; 2019 Sep; 28(3):289-296. PubMed ID: 31517325
[TBL] [Abstract][Full Text] [Related]
18. Serum immunoreactive collagen IV detected by monoclonal antibodies as a marker of severe fibrosis in patients with non-alcoholic fatty liver disease.
Aida Y; Abe H; Tomita Y; Nagano T; Seki N; Sugita T; Itagaki M; Ishiguro H; Sutoh S; Aizawa Y
J Gastrointestin Liver Dis; 2015 Mar; 24(1):61-8. PubMed ID: 25822435
[TBL] [Abstract][Full Text] [Related]
19. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.
Boursier J; Guillaume M; Leroy V; Irlès M; Roux M; Lannes A; Foucher J; Zuberbuhler F; Delabaudière C; Barthelon J; Michalak S; Hiriart JB; Peron JM; Gerster T; Le Bail B; Riou J; Hunault G; Merrouche W; Oberti F; Pelade L; Fouchard I; Bureau C; Calès P; de Ledinghen V
J Hepatol; 2019 Aug; 71(2):389-396. PubMed ID: 31102719
[TBL] [Abstract][Full Text] [Related]
20. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]